Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBd Combination Therapy for Previously Untreated Multiple Myeloma
NCT00561743Phase 2Completed
- Sponsor
- Janssen Ortho
- Start
- Nov 2005
- Primary completion
- May 2007
- Modality
- DNA Intercalators/Alkylators, Modified Peptides
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and doxorubicin in multiple myeloma (MM), sponsored by Janssen Ortho. Primary endpoint: Complete Response and Near Complete Response Rate. Started Nov 2005; status: completed.
02
Drugs
bortezomibdoxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00561743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561743.